DATATOP: A decade of neuroprotective inquiry

  title={DATATOP: A decade of neuroprotective inquiry},
  author={Ira Shoulson},
  journal={Annals of Neurology},
  • I. Shoulson
  • Published 1 September 1998
  • Psychology
  • Annals of Neurology
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a… 

Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

Levodopa‐treated Parkinson's disease patients who had been treated with deprenyl for up to 7 years, compared with patients who were changed to a placebo after about 5 years, experienced slower motor decline and were more likely to develop dyskinesias but less likely to developed freezing of gait.

A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis

Although f -tocopherol did not appear to affect the survival and motor function in ALS, patients receiving riluzole plus f -ocopherol remained longer in the milder states of the ALS Health State scale and showed changes in biochemical markers of oxidative stress.

The Fabulous Neuroprotection of Selegiline: Memoir and Prospectus

  • W. Landau
  • Medicine
    Journal of child neurology
  • 2010
The thrust of my critique was not that protective function was disproved, but rather that it was not proved; the unexpected discovery from consistent clinical evaluations that deprenyl directly improved the symptoms of parkinsonism.

Trial of Cinpanemab in Early Parkinson's Disease.

In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

Neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin E is efficacious in slowing disease progression in ALS as an add-on therapy to riluzol.

Neuroprotection in Parkinson's disease.

  • A. Schapira
  • Biology, Psychology
    Parkinsonism & related disorders
  • 2009

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration

Compared with selegiline, rasagiline is more potent in protecting neurodegeneration induced by UPS impairment and may, therefore, exert disease‐modifying effects in PD.

Targeting the Prodromal Stage of Alzheimer’s Disease: Bioenergetic and Mitochondrial Opportunities

The importance of early therapeutic intervention during the prodromal stage that precedes irreversible degeneration in AD is discussed, and a systems biology approach that targets the bioenergetic system rather than a single component of this system is focused on.

Design of clinical trials of gene therapy in Parkinson disease